ImmuPharma Reports Positive Results For Lupuzor Trial
Published: 19-Nov-2009
Drug, well tolerated with adverse event rates lower
ImmuPharma has announced the final results from a Phase IIb trial of Lupuzor in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor administered at 200mcg once-a-month for 3 months plus standard of care achieved improvement in patient response rate as measured by the combined score compared to placebo plus standard of care. The study results also show that Lupuzor was generally well tolerated, with adverse event rates lower with Lupuzor when compared to placebo.
The Phase IIb study was a randomised, double-blind placebo controlled, dose-ranging study in 150 patients designed to evaluate the efficacy of Lupuzor in a three-month treatment period of either subcutaneous (SC) injection of 200mcg once-a-month (4qw) or 200mcg twice-a-month (2qw) or placebo in addition to standard of care and followed by a 3 month follow-up period.
The primary efficacy endpoint of the study was based on the combined score, which is defined by: a reduction from baseline of at least 4 points on the 2K-sledai disease activity scale; no worsening of disease as measured by the Physician's Global Assessment; and no new BILAG A organ domain score and no more than one new BILAG B organ domain score. An additional end-point was the response rate based only on the decrease of the sledai score by 4 points.
An interim analysis was performed and included 125 patients out of the ITT population having completed by mid November 2008 the week 12 assessments, approximately half of them having also completed the 12 week follow-up period. These results were announced in January 2009 indicating that Lupuzor administered at a 200mcg dose once-a month for 3 months was statistically significantly superior to placebo, using a decrease of 4 points of the sledai score to define a responder with
drop-outs being considered according to the protocol as non-responders. As the study showed an improvement even with a much lower number of patients, ImmuPharma decided to stop the recruitment of further patients. All patients already recruited completed the study according to protocol.
All treatments (Lupuzor or placebo) were administered in addition of standard of care which may include patients on low dose steroids (less than 80mg prednisone/week). 200mg of Lupuzor administered once-a-month during 3 months (total 600mg) achieved a clinically and statistically meaningful improvement of the moderate to severe subgroup. An analysis after a further 12 week follow-up (with only standard of care) revealed that the responder rates further increased to reach about 70% in the moderate to severe subgroup compared to 59% on placebo. Lupuzor was well tolerated and its safety profile was better than placebo with less drop-outs (1 vs 8) and less serious AEs leading to discontinuation.
Network Sites

Suppliers To This Sector
Browse A-Z
ADAPT Localization
The Translation and Localization Specialists ...
Almac
Drug Development Solutions ...
Axiom Real Time Metrics
EDC Solutions ...
BioClinica
Global Clinical Trial Solutions. Real-World Results ...
BioKinetic Europe
Phase I/II Contract Research Organisation ...
C3 Research Associates
Clinical Research Development and Management Group ...
White Papers
Browse A-Z
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model
Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
Enabling Drug Delivery Deal Making
Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...
Automating Training Control Processes to Comply with FDA Requirements
Well-managed training programs minimize the risk of non-compliance and improve product qua ...
TNO Pharma Services: From Discovery to the Clinic
Our kinetics & metabolism experts can help you select and further develop your candidate d ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully